# COMPUTER ALERT FATIGUE – DON'T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS

Dan Malone, RPh, PhD Professor University of Arizona

# Disclosures

 I, Daniel Malone, have no financial relationships to disclose

- Funding
  - AHRQ U18 HS017001-01 PI: Woosley;
  - AHRQ 1R13HS021826-01 PI Malone;
  - AHRQ 1R13HS018307-01 PI: Malone
  - Centers for Disease Control and Prevention PI: Lipton



# The Problem!



You wouldn't believe how many **BIG BAD** drug-drug interactions there are. Just ask your doctor about all the DDI alerts she gets!



# Drug Interaction Knowledge and Information Sources

- Prescriber knowledge is lacking<sup>1,2</sup>
  - 42.7% of drug pairs correctly identified<sup>1</sup>
- Information sources use by prescribers for DDIs<sup>3</sup>
  - Pharmacists 68.4% also lacking knowledge<sup>4</sup>
  - PDA 15.8% similar to online resources
  - Alerts 10.8% *known to be problematic*
  - Other sources 5.1% e.g., compendia, labeling

1) Ko et al. *Drug Saf.* 2008;31(6):525-536. 2) Glassman. *Med Care.* 2002;40(12):1161-1171. 3) Ko et al. *Res Social Adm Pharm.* 2008;4(4):355-366. 4) Weideman et al. Am J Health Syst Pharm 1999 56: 1524-1529.

# Terminology

#### • Drug-drug interaction (DDI):


Clinically meaningful alteration in the effect of one drug (*object*) as a result of coadministration of another (*precipitant*)

 Potential drug-drug interaction (PDDI):
 Co-prescription or co-administration of drugs known to interact, regardless of whether harm ensues

#### Sensitivity of Computer Software to Detect Drug Interactions in Arizona Pharmacies (N=64)

Warfarin + sulfamethoxazole/trimethoprim

Warfarin + naproxen Warfarin + gemfibrozil Warfarin + fluconazole Warfarin + amiodarone Simvastatin + gemfibrozil Simvastatin + amiodarone Simvastain + itraconazole Nitroglycerin + sildenafil Digoxin + itraconazole Digoxin + clarithromycin Digoxin + amiodarone Carbamazepine + clarithromycin



Saverno et al. JAMIA; 2011:18:32-37



# **Concordance Among DDI Compendia**



#### DRUG-REAX<sup>®</sup> System

from MICROMEDEX



# "Major" Drug Interactions Listed by Compendium

Compendium	No.
MicroMedex DRUG-REAX®	275
Evaluation of Drug Interactions	64
Drug Interactions: Analysis and Management	94
Drug Interaction Facts	141
Total	406*

\* Sum of column exceeds total due to duplicate interactions.



# Agreement Among Four Drug Interaction Compendia

- DDIs in 4 of 4: 2.2% (9/406)
- DDIs in 3 of 4: 8.6% (35/406)
- DDIs in 2 of 4: 17.4% (71/406)
- DDIs in 1 of 4: 71.7% (291/406)

Intra-class Correlation Coefficient: -0.092

Abarca J et al. J Am Pharmacist Assn 2003: 44:136-141.

# Drug Interaction Knowledge and Information Sources

- Prescriber knowledge is lacking<sup>1,2</sup>
  - 42.7% of drug pairs correctly identified<sup>1</sup>
- Information sources use by prescribers<sup>3</sup>
  - Pharmacists 68.4% also lacking knowledge<sup>4</sup>
  - PDA 15.8% similar to online resources
  - Alerts 10.8% *known to be problematic*
  - Other sources 5.1% e.g., compendia, labeling

1) Ko et al. *Drug Saf.* 2008;31(6):525-536. 2) Glassman. *Med Care.* 2002;40(12):1161-1171. 3) Ko et al. *Res Social Adm Pharm.* 2008;4(4):355-366. 4) Weideman et al. Am J Health Syst Pharm 1999 56: 1524-1529.



# Market Removals Due to Drug-Drug Interactions

- Terfenadine (Seldane®) 1998
- Mibefradil (Posicor®)- 1998
- Astemizole (Hismanal®) 1999
- Cisapride (Propulsid®) 2000
- Cerivastatin (Baycol®) 2001

# **DDI Prevalence in Elderly**

- Elderly veterans with new DDI at ED discharge:<sup>1</sup> 13%
- Older adults exposed to a "major" DDI:<sup>2</sup> 4%
- Medicare Part D
  enrollees exposed to
  certain DDIs: 7.3%



1) J Am Geriatr Soc. 2008;56:875-80. 2) JAMA. 2008;300:2867-78.

Question: What factors contribute to patients being exposed to potential DDIs?

- A. Evidence for DDIs is lacking
- B. Conflicting information among DDI compendia
- C. There are too many irrelevant DDI alerts
- D. DDI knowledge is poor among health professionals
- E. All of the above



# Question: What factors contribute to patients being exposed to potential DDIs?

- A. Evidence for DDIs is lacking
- B. Conflicting information among DDI compendia
- C. There are too many irrelevant DDI alerts
- D. DDI knowledge is poor among health professionals
- E. All of the above




# Health Systems Approach to DDIs

- Evidence for DDIs is lacking
  - Very few well-controlled studies
- Lack of concordance among DDI compendia<sup>1</sup>
  - Differing severity rating systems, terminology, methodologies
- Limitations of DDI clinical decision support<sup>2-4</sup>
  - "Alert fatigue"
  - High rates of alert override


1) Abarca et al. J Am Pharm Assoc (2003). 2004;44(2):136-141. 2) Grizzle et al. Am J Manag Care. 2007;13(10):573-578. 3) Murphy et al. Am J Health Syst Pharm. 2004;61(14):1484-1487. 4) Abarca et al. J Manag Care Pharm. 2006;12(5):383-389.

# Improving Knowledge to Prevent Exposure to Potential DDIs

- Understanding basic concepts allows for more rationale DDI predictions
- Prevent adverse DDIs by making patient- and situation-specific assessments
- When appropriate:
  - Avoid concomitant administration
  - Implement alternative therapeutic strategies
  - Take precautionary measures



Hansten PD, Horn JR. Modified from: James Reason, Human Error, 1990



Hansten PD, Horn JR. Modified from: James Reason, Human Error, 1990

# Pharmacokinetic Drug Interactions


### GI absorption

- Drug binding in GI tract
- Alterations in GI motility
- Alterations in GI pH

### Plasma protein binding

? clinical significance

- Cytochrome P450
  - Induction or inhibition
- Transport proteins
  - Induction or inhibition



Question: Which of the following is classified as a pharmacokinetic DDI?

- A. Oral contraceptives-carbamazepine
- B. Tadalafil-isosorbide dinitrate
- C. Sotalol-levofloxacin
- D. Spironolactone-ramipril
- E. Benazepril-aspirin





Question: Which of the following is classified as a pharmacokinetic DDI?

- A. Combination oral contraceptivescarbamazepine
- B. Tadalafil-isosorbide dinitrate
- C. Sotalol-levofloxacin
- D. Spironolactone-ramipril
- E. Benazepril-aspirin



# **Drug Interaction Mechanisms**

- Pharmacodynamic
  - Additive or antagonistic pharmacologic effects
- Pharmacokinetic
  - Absorption
  - **Distribution**
  - Metabolism
  - Excretion

Altered drug elimination is the most common cause of adverse PK DDIs



# Drug Interaction Mechanisms (continued)


# **Pharmacokinetic Interactions**


## GI absorption

- Drug binding in GI tract
- Alterations in GI motility
- Alterations in GI pH
- Plasma protein binding
  - Not clinically significant
- Cytochrome P450 (CYP)
  - Induction or inhibition
- Transport proteins (P-glycoprotein [PGP])
  - Induction or inhibition



# Cytochrome P450 (CYP) Enzymes






Macrolides, Azole antifungals



# Most Drug-Drug Interactions Are Due to Different Prescribers!


- A. Yes
- B. No
- C. Sometimes
- D. Don't know

# Analysis of Arizona Medicaid Claims



## Who Prescribes Drug-Drug Interactions?

#### Potential Drug-Drug Interactions by the Same Prescriber



# Case


- 67-year-old woman
- Diagnosed with pneumonia after mitral valve repair
- Developed the following on electrocardiogram...

Past Medical History

- Chronic atrial fibrillation
- •Heart failure
- •Hypertension
- •Hypothyroidism

•Obesity

Medications New medications: •Amiodarone •Levofloxacin



Case adapted from: Proc (Bayl Univ Med Cent). 2006;19(4):345-6.

Question: What risk factors for TdP did this patient have?

- A. Concomitant QT-prolonging drugs
- B. Female sex
- C. Advancing age
- D. Cardiac disease
- E. All of the above



QTc=rate-corrected QT interval on electrocardiogram; TdP=torsades de pointes

Question: What risk factors for TdP did this patient have?

- A. Concomitant QT-prolonging drugs
- B. Female sex
- C. Advancing age
- D. Cardiac disease
- E. All of the above



QTc=rate-corrected QT interval on electrocardiogram; TdP=torsades de pointes

#### Usually Avoid This Combination Amiodarone-Levofloxacin

- Additive risk of QTc prolongation
- Potentially fatal
- Data limited regarding arrhythmogenic risk of drugs alone or in combination

#### **Risk Factors for TdP**

- Concomitant QTc-prolonging drugs
- Female
- Advancing age
- Cardiac disease
- Bradycardia
- Familial history long QT syndrome
- Electrolyte disturbances (e.g., low K<sup>+</sup>, Mg<sup>++</sup>, Ca<sup>++</sup>)

QTc=rate-corrected QT interval on electrocardiogram; TdP=torsades de pointes

# Prolonged QT Risk Groups

#### **Risk of Torsades**

- Disopyramide
- Procainamide
- Quininidine
- Amiodarone
- Dofetilide
- Ibutilide
- Sotalol
- Clarithromycin
- Erythromcyin

Possible Risk of Torsades

- Flecainide
- Gemifloxacin
- Levofloxacin
- Moxifloxacin
- Ofloxacin
- Azithromycin

Conditional Risk of Torsades

Ciprofloxacin

QT drug lists by risk groups. Arizona Center for Education and Research on Therapeutics. Available at: http://www.azcert.org/medical-pros/drug-lists/drug-lists.cfm

# Case 2



- 77-year-old woman
- Presented with episodes of vomiting bright red blood and passing bloody stools
- INR 2.1 (target 2.5-3.5)
- Severe dyspnea due to aspiration
- Expired from hypotension and multisystem failure

Case adapted from: Med J Aust. 1996;164(11):700-1.

#### **Past Medical History**

- Aortic valve replacement
- Atrial fibrillation
- •Heart failure
- •Hypertension
- Ischemic heart disease

Medications Chronic medications: •Warfarin •Furosemide •Lisinopril •Metoprolol New medication: •Ibuprofen (OTC) Question: Which of the following are appropriate treatments for a patient on chronic warfarin therapy who requires an analgesic in order to <u>minimize</u> the risk of GI bleeding?

- A. Acetaminophen with codeine
- B. Celecoxib
- C. Naproxen
- D. All of the above
- E. None of the above



Question: Which of the following are appropriate treatments for a patient on chronic warfarin therapy who requires an analgesic in order to <u>minimize</u> the risk of GI bleeding?

- A. Acetaminophen with codeine
- B. Celecoxib
- C. Naproxen
- D. All of the above
- E. None of the above



# Warfarin-NSAID

- Additive risk of bleeding
  - Some NSAIDs may also alter warfarin PK
- Considerable increased risk of GI bleeding<sup>1</sup>
  - 13-fold higher risk hospitalization for hemorrhagic PUD vs. neither drug; 4-fold higher risk with either drug alone

Usually Avoid This Combination

- Co-prescribing common despite risks<sup>2,3</sup>
  - Most common among top 25 clinically significant outpatient DDIs (242.7 per 1,000 warfarin recipients)

1) Shorr et al. Arch Intern Med. 1993;153(14)1665-70. 2) Malone et al. J Am Pharm Assoc (2003). 2004;44(2):142-51. 3) Malone et al. Am J Health Syst Pharm. 2005;62(19):1983-91.

#### **Usually Avoid This Combination**

# Warfarin-NSAID (continued)

- Acetaminophen or opioids preferred
  - Limit acetaminophen & monitor
- COX-2 inhibitors
  - No conclusive evidence for lower risk
- Aspirin
  - Antiplatelet aspirin therapy increases minor bleeding risk
- If combined use necessary
  - Monitor for bleeding
  - Consider prophylaxis for NSAID-associated GI injury

## Case 3

Question: A 50-year-old man with chronic atrial fibrillation and a history of epilepsy is stabilized on warfarin and carbamazepine. His neurologist wants to discontinue the carbamazepine. What is the primary concern regarding his anticoagulation if the carbamazepine is <u>stopped</u>?

- A. Increased risk of thromboembolism
- B. Excessive anticoagulation
- C. There are no major concerns with this decision
- D. None of the above



Question: A 50-year-old man with chronic atrial fibrillation and a history of epilepsy is stabilized on warfarin and carbamazepine. His neurologist wants to discontinue the carbamazepine. What is the primary concern regarding his anticoagulation if the carbamazepine is <u>stopped</u>?

- A. Increased risk of thromboembolism
- B. Excessive anticoagulation
- C. There are no major concerns with this decision
- D. None of the above



## Warfarin-Carbamazepine

- Carbamazepine induces warfarin metabolism
- The warfarin dose was likely previously increased to adjust for enzyme induction
- Stopping the enzyme inducer would increase the warfarin concentration
- The warfarin dose would be then excessive if not adjusted
- Consider effects of stopping the precipitant drug generally not detected by software

Question: What is the mechanism of the interaction between carbamazepine and clarithromycin?

- A. Carbamazepine inhibits the metabolism of clarithromycin by CYP3A4
- B. Clarithromycin inhibits the metabolism of carbamazepine by CYP3A4
- C. Carbamazepine induces the metabolism of clarithromycin by CYP2D6
- D. Clarithromycin induces the metabolism of carbamazepine by CYP2D6



Question: What is the mechanism of the interaction between carbamazepine and clarithromycin?

- A. Carbamazepine inhibits the metabolism of clarithromycin by CYP3A4
- B. Clarithromycin inhibits the metabolism of carbamazepine by CYP3A4
- C. Carbamazepine induces the metabolism of clarithromycin by CYP2D6
- D. Clarithromycin induces the metabolism of carbamazepine by CYP2D6



Question: Which of the following would be appropriate alternatives to clarithromycin for a patient taking carbamazepine in order to avoid an interaction?

- A. Azithromycin
- B. Cefdinir
- C. Levofloxacin
- D. All of the above
- E. None of the above



Question: Which of the following would be appropriate alternatives to clarithromycin for a patient taking carbamazepine in order to avoid an interaction?

- A. Azithromycin
- B. Cefdinir
- C. Levofloxacin
- D. All of the above
- E. None of the above



Take Precautions with this Combination

# Carbamazepine-Clarithromycin

- Clarithromycin inhibits carbamazepine metabolism by CYP3A4
- Consider alternatives
  - Azithromycin or non-macrolide depending on infection and susceptibilities
- If combined use necessary, adjust and monitor
  - Temporarily decrease carbamazepine dosage (30%-50%) and monitor concentrations
  - Warn patients of toxicity symptoms

## Case 4

- 45-year-old postmenopausal woman
- Underwent surgery, chemotherapy, and radiation therapy, followed by 6 months tamoxifen
- Pharmacogenetic testing for CYP2D6: extensive metabolizer
- Developed recurrence of depressive symptoms

Past Medical History

ER+ invasive breast

cancer

•Major depressive disorder

Medications Chronic medications: •Tamoxifen



Case adapted from: Am J Psychiatry. 2008;165(10):1251-5.

Question: Which of the following agents is thought to <u>compromise</u> the efficacy of tamoxifen?

- A. Citalopram
- B. Fluoxetine
- C. Sertraline
- D. Venlafaxine
- E. All of the above





Question: Which of the following agents is thought to <u>compromise</u> the efficacy of tamoxifen?

- A. Citalopram
- B. Fluoxetine
- C. Sertraline
- D. Venlafaxine
- E. All of the above





#### Take Precautions with this Combination

## Tamoxifen-Fluoxetine

- Fluoxetine inhibits conversion of prodrug tamoxifen by CYP2D6 to its primary active metabolite
- Concern regarding increased risk breast cancer recurrence
- Alternative antidepressants
  - Citalopram, sertraline, and venlafaxine do <u>not</u> significantly inhibit CYP2D6
  - Bupropion, duloxetine, and paroxetine also <u>inhibit</u> <u>CYP2D6</u>
- Reasonable to avoid known CYP2D6 inhibitors based on current data

### Case 5



# Past Medical HistoryHypertension

•Hyperlipidemia

Medications Chronic medications: •Simvastatin •Lisinopril •Aspirin New medication: •Itraconazole

- 74-year-old man
- Started treatment for toenail infection
- 3 weeks later, lower extremity pain while golfing
- Pain progressed to upper extremities and neck, urine turned brown
- CK 22,800,000 U/L (reference range: 32-267)

CK=creatine kinase Case Adapted from: Ann Pharmacother. 2006;40(4):753-7. **Question:** Which of the following would be appropriate strategies to avoid an interaction between simvastatin and itraconazole?

- A. Use an alternative antifungal (e.g., terbinafine)
- B. Temporarily stop the simvastatin during shortterm itraconazole therapy
- C. Switch to an alternative statin during long-term itraconazole therapy
- D. All of the above
- E. None of the above



**Question:** Which of the following would be appropriate strategies to avoid an interaction between simvastatin and itraconazole?

- A. Use an alternative antifungal (e.g., terbinafine)
- B. Temporarily stop the simvastatin during shortterm itraconazole therapy
- C. Switch to an alternative statin during long-term itraconazole therapy
- D. All of the above
- E. None of the above



# Simvastatin-Itraconazole

- Itraconazole inhibits simvastatin metabolism by CYP3A4
- Antifungal alternatives
  - Consider terbinafine (not CYP3A4 inhibitor) or ciclopirox nail lacquer (not absorbed)
  - Avoid azole antifungals (inhibit CYP3A4)
- Hold simvastatin (short-term)
  - NOT in unstable angina or immediately post-MI
- Statin alternatives
  - Consider fluvastatin, rosuvastatin or pravastatin (not CYP3A4 substrates)
  - Avoid lovastatin and atorvastatin (to a lesser extent)

Question: Which of the following would be preferred therapeutic alternatives to simvastatin for a patient on chronic amiodarone therapy in order to avoid an interaction?

- A. Atorvastatin
- B. Lovastatin
- C. Rosuvastatin
- D. All of the above



E. None of the above – this is a class effect

Question: Which of the following would be preferred therapeutic alternatives to simvastatin for a patient on chronic amiodarone therapy in order to avoid an interaction?

- A. Atorvastatin
- B. Lovastatin
- C. Rosuvastatin
- D. All of the above



E. None of the above – this is a class effect

# Simvastatin-Amiodarone

- Amiodarone inhibits simvastatin metabolism by CYP3A4
- Statin alternatives
  - Consider fluvastatin, rosuvastatin, pravastatin (not metabolized by CYP3A4)
  - Avoid lovastatin and atorvastatin (to a lesser extent)
- If combined use necessary
  - Maximum simvastatin dose: 20 mg/day
  - Warn patients to report muscle pain, tenderness, or weakness
     Bisk Easters for Phabdomyolysis

#### **Risk Factors for Rhabdomyolysis**

- Advanced age (>65 years)
- Uncontrolled hypothyroidism
- •Renal impairment

## **Clinically Relevant Interactions**

Object Medications	Precipitant Medication	DDI-Specific Hospitalization: Odds Ratio 95% Cl	DDI-Specific Medical Outcome: Odds Ratio 95% CI	Total Healthcare Cost Difference in Follow up Period
Amiodarone and/or Sotalol	Macrolides or quinolones	1.13 (0.94-1.36)	1.52 (1.40-1.66)	\$1923 (\$1348 - \$2497)
Amiodarone	Macrolides	1.21 (0.60-2.46)	1.84 (1.32-2.55)	\$2784 (\$1509 - \$4059)
Amiodarone	Quinolones	1.16 (0.94-1.42)	1.57 (1.43-1.74)	\$2756 (\$2011 - \$3500)
Carbamazepine	Azole Antifungals	3.00 (1.09-8.25)	2.40 (1.57-3.67)	\$785 (\$382 - \$1187)
Carbamazepine	Macrolides	10.00 (1.28-78.12)	2.00 (1.23-3.27)	\$1181 (\$722 - \$1640)

## **Clinically Relevant Interactions**

Object Medication	Precipitant Medication	DDI-Specific Hospitalization: Odds Ratio 95% CI	DDI-Specific Medical Outcome: Odds Ratio 95% Cl	Total Healthcare Cost Difference in Follow up Period
Lovastatin or Simvastatin	Azole Antifungals	2.00 (0.50-8.00)	1.33 (0.46-3.84)	\$994 (\$810 - \$1177)
Lovastatin or Simvastatin	Macrolides	-	9.00 (1.14- 71.04)	\$872 (\$781 - \$962)
Lithium	NSAIDS	2.00 (0.37-10.92)	3.22 (1.90-5.47)	\$681 (\$491 - \$870)

## Warfarin Interactions

Object Medication	Precipitant Medication	DDI-Specific Hospitalization: Odds Ratio 95% CI	DDI-Specific Medical Outcome: Odds Ratio 95% CI	Total Healthcare Cost Difference in Follow up Period
Warfarin	Amiodarone	2.26 (1.89-2.70)	2.24 (2.02-2.48)	\$1656 (\$1382 - \$1930)
Warfarin	Sulfamethox- azole	3.40 (2.53-4.57)	2.87 (2.42-3.41)	\$3252 (\$2869 - \$3634)
Warfarin	Metronidazole	4.72 (3.22-6.91)	7.70 (6.03-9.83)	\$4533 (\$4043 - \$5022)
Warfarin	Fluconazole or Voriconazole	2.37 (1.70-3.31)	3.62 (2.90-4.53)	\$6130 (\$5377 - \$6883)
Warfarin	Fenofibrate or Gemfibrozil	1.41 (1.00-1.99)	1.67 (1.39-2.02)	\$467 (\$288 - \$646)
Warfarin	Statins	1.61 (1.37-1.89)	1.83 (1.67-2.00)	\$515 (\$424 - \$606)
Warfarin	NSAIDS	3.26 (2.49-4.26)	2.45 (2.09-2.87)	\$1940 (\$1763 - \$2117)

# Other Interactions to Avoid Sildenafil and Nitrates

•Pharmacodynamic interaction: additive hypotensive effects

•flushing, dizziness, headache, death

•Predisposing factors:

- > 65 years old
- Hepatic impairment
- Severe renal impairment

•Patient Management:

• Co-administration of nitrates with sildenafil may be appropriate under certain conditions.

Drug	ACC/AHA Recommendations for nitrate administration
sildenafil	24 hours
tadalafil	48 hours
vardenafil	24 hours (not in guideline)

# Statins and Gemfibrozil (Fibrates)

#### • Proposed mechanism of interaction:

- Displacement of protein binding
- Atypical enzyme interaction
- Direct action on myocytes
- Interference with multiple drug resistance protein (MDRP)

#### Risk of co-administration:

Severe myopathy, Rhabdomyolysis, Acute renal failure

#### • Evidence:

- PK studies and reviews of FDA Adverse Event Reporting databases
- Overall incidence is rare but serious

>80% of reported rhabdomyolysis cases resulted in hospitalization for renal failure

- Risk is higher for gemfibrozil than fenofibrate (15x)
- Simvastatin has highest reporting rate (4/100,000)

# Colchicine-Clarithromycin

- Colchicine is substrate for CYP3A4 and PGP
  - Clarithromycin is potent inhibitor of both
- FDA database: 60 fatalities (as of 2010)
- Retrospective case series of 88 patients
  - 9 expired
- Adverse outcomes
  - Pancytopenia
  - GI effects: diarrhea, N/V, pain
  - Myopathy
  - Multi-organ failure
- Onset
  - Time to symptoms approximately 4 days
  - Time to death (< 2 weeks)</li>

# Summary

- Drug interaction knowledge is poor among health professionals
- Many DDIs result from multiple prescribers
  but not all
- Interactions can be harmful

  - Morbidity
  - Costs

# **RED Flag Medications**

- Warfarin
- Macrolide antibiotics
  - Clarithromycin / erythromycin
- Azole antifungals
- Anti-epileptic medications
- Amiodarone
- Colchicine

**Questions?**